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Introduction {#sec005}
============

Among inpatients, acute kidney injury (AKI) is a common complication, with a high incidence and poor prognosis. AKI consumes a large amount of societal medical resources \[[@pone.0171076.ref001]\]. Provide specific therapies for the cause of AKI. Apply renal replacement therapy if necessary. In recent years, more studies have concentrated on the relationship between AKI and chronic kidney disease (CKD). Compared with young patients, elderly AKI patients can easily progress to CKD or end-stage renal disease (ESRD) \[[@pone.0171076.ref002]--[@pone.0171076.ref004]\]. Urinary kidney injury molecule-1 (uKIM-1) is a marker of epithelial injury of renal tubules, and it is elevated in the early stages of AKI \[[@pone.0171076.ref005]\]. Different uKIM-1 levels are associated with various degrees of renal injuries. For this study, the factors influencing kidney prognosis were analyzed in a group of elderly AKI patients to determine the markers of early prognosis.

Subjects and methods {#sec006}
====================

1.1 Study subjects {#sec007}
------------------

Male or female inpatients (≥18 years old) with complete clinical data and who were diagnosed with AKI or acute-on-chronic kidney injury (A on C) between April 2013 and April 2015 were enrolled in this study. Patients with a life expectancy of less than one year due to malignant diseases were excluded.

AKI was defined and staged according to the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Acute Kidney Injury\[[@pone.0171076.ref006]\].

The study was approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University and all participants gave written informed consent.

1.2 Sampling {#sec008}
------------

Fresh urine and blood samples were obtained from each patient at the time of the final AKI diagnosis, at 24 h and 48 h after the diagnosis, and at the three-month, six-month and twelve-month follow-ups. The samples were submitted to a biochemical laboratory for testing.

First, 10 mL fresh urine was obtained from each patient at the final AKI diagnosis, and the urine was centrifuged at 1000×g for 15 min. Then, supernatant was placed into an Eppendorf tube and preserved at -80°C until testing.

1.3 Detection of indicators {#sec009}
---------------------------

Serum creatinine (sCr) and urine creatinine (uCr) levels were analyzed using enzymatic methods. A simplified Modification of Diet in Renal Disease (MDRD) formula was adopted to estimate the glomerular filtration rate (GFR), eGFR = 186×(sCr/88.4)^-1.154^×age^-0.203^X(0.742, female) \[[@pone.0171076.ref007]\].

A sandwich enzyme linked immunosorbent assay (ELISA) was performed to detect urine kidney injury molecule-1 (uKIM-1) using a kit produced by the American R&D Corporation (Minneapolis, USA). The concentration of the tested sample (undiluted urine) was calculated using the standard curve and expressed in ng/mg after synchronous uCr correction.

1.4 Grouping {#sec010}
------------

Patients ≥60 years old were divided into a transient AKI group and a non transient AKI group based on the changes in renal function. Transient AKI was defined as reversal within 48 h\[[@pone.0171076.ref008]\].

During the one year of follow-up, renal function changes were observed, and the risk factors for progressive deterioration of renal function were analyzed. Progressive deterioration of renal function is defined as a one-stage drop in GFR, accompanied by a 25% or greater drop in eGFR compared with baseline \[[@pone.0171076.ref009]\].

1.5 Statistical analyses {#sec011}
------------------------

SPSS13.0 statistical software was used for the analyses. Normal distribution measurement data are expressed as x±s, and a t-test was used for between-group comparisons. Non-normally distributed data are expressed as the median (M) and interquartile range (P25, P75), and the Wilcoxon rank-sum test was used for between-group comparisons. The ROC curve and the area under curve were adopted to calculate the sensitivity and specificity, respectively. Logistic regression was used to analyze the related risk factors that influenced kidney prognosis. Cox multifactor regression analysis was used to investigate the relationship between all risk factors and the life span of the kidney. The patient survival rate was analyzed using the Kaplan-Meier life survival curve, and a P\<0.05 difference was considered to be statistically significant.

Results {#sec012}
=======

2.1 General information {#sec013}
-----------------------

A total of 258 patients were screened, and 201 patients were enrolled in the study. Seventeen patients were excluded due to loss of follow-up. Eventually, 184 AKI patients were enrolled in the study, including 79 patients ≥60 years old and 105 patients \<60 years old ([Fig 1](#pone.0171076.g001){ref-type="fig"}).

![Study flow chart.](pone.0171076.g001){#pone.0171076.g001}

These 184 AKI patients (age range: 18 to 99 years) had a median age of 53.00 years (31.00, 64.75), with a 1.75:1 ratio of males to females. The mean follow-up period was 12.2±1.06 months. The baseline Scr, baseline eGFP and baseline 24 h total urinary protein levels were 98.87 μmol/L (76.85, 211.85), 66.68 mL/min/1.73 m^2^ (28.10, 94.18)and 3.78 g (1.47, 9.08), respectively. A total of 71 patients had a previous history of chronic renal disease. In AKI, the uKIM-1 level and peak creatinine values were 2.37 ng/mg (1.10, 6.22) and 215.00 μmol/L (124.40, 331.00), respectively. Stage 1 disease was found in 123 patients, stage 2 was found in 26 patients, and stage 3 was found in 35 patients. The incidence of non transient AKI was 53.26%. The etiologies of AKI were assessed clinically, including renal blood hypoperfusion or ischemia (22%), renal toxicity injury (20%), infectious factors (23%), renal glomerular disease aggravation or activity (19%), and obstruction (11%). After three months of follow-up, renal functional rehabilitation was observed in 59.78% of the patients. After one year of follow-up, progressive deterioration of renal function was found in 39.67% of the patients ([Table 1](#pone.0171076.t001){ref-type="table"}).

10.1371/journal.pone.0171076.t001

###### General condition of patients.

![](pone.0171076.t001){#pone.0171076.t001g}

  Characteristics                           N = 184
  ----------------------------------------- ------------------------
  Age, years                                53.00(31.00, 64.75)
  Male sex (N, %)                           117(63.59%)
  Oliguria (N, %)                           9(4.9%)
  Baseline serum creatinine (μmol/l)        98.87(76.85, 211.85)
  Baseline estimated GFR(ml/min/1.73m^2^)   66.68(28.10, 94.18)
  Baseline 24hUTP(g/24h)                    3.78(1.47, 9.08)
  sAlb(g/l)                                 33.30(24.00, 40.25)
  Hb(g/L)                                   119.00(99.25, 140.00)
  ALT(IU/L)                                 14.00(10.00, 23.00)
  AST(U/L)                                  17.00(14.00, 25.75)
  Ca(mmol/L)                                2.08(1.99, 2.22)
  P(mmol/L)                                 1.32(1.10, 1.56)
  K(mmol/L)                                 3.90(3.40, 4.30)
  HCO~3~^-^(mmol/L)                         24.20(20.90, 26.40)
  hsCRP(mg/L)                               2.40(0.80, 8.17)
  *Cause of AKI*                            *N(%)*
  ischemia                                  40(21.74%)
  Nephrotoxin exposure                      37(20.11%)
  Infection                                 42(22.83%)
  Glomerular disease                        35(19.02%)
  obstruction                               21(11.41%)
  others                                    9(4.90%)
  *AKI stage*                               
  Stage 1                                   123
  Stage 2                                   26
  Stage 3                                   35
  Peak serum creatinine (μmol/l)            215.00(124.40, 331.00)
  uKIM-1(ng/mg)                             2.37(1.10, 6.22)
  FeNa≥1%                                   126(68.48%)
  RFI≥1%                                    136(73.91%)
  non transient AKI                         98(53.26%)
  Recovery within 3 months                  110(59.78%)
  Ultimate outcome                          73(39.67%)

2.2 Condition analysis for elderly AKI patients {#sec014}
-----------------------------------------------

Comparing AKI patients ≥60 years old (N = 79) with patients \<60 years old (N = 105), no significant differences were observed in sex, baseline creatinine level, proportion of pre-existing chronic renal disease and AKI staging. The etiologies of AKI in elderly patients primarily involved renal blood hypoperfusion or ischemia, renal toxicity injury and infections.

Elderly AKI patients ≥60 years old presented with low baseline eGFR levels and higher peak values of creatinine during the occurrence of AKI. Patients with FeNa≥1% and RFI≥1% accounted for a higher proportion of patients, and the incidence of non transient AKI was higher in these patients.

For the elderly AKI patients ≥60 years old, higher uKIM-1 levels were observed during the occurrence of AKI, but no significant difference was identified between the elderly AKI patients (≥60 years old) and those AKI patients who aged from 18 to 60.

For patients ≥60 years of age, renal functional rehabilitation was observed in 45.57% patients within three months after being diagnosed with AKI, which was significant compared with patients \<60 years old (70.48%). After the one-year follow-up period, progressive deterioration of renal function was observed in 60.76% of the patients ≥60 years old, a rate that was significantly higher than that of patients \<60 years old (23.81%) ([Table 2](#pone.0171076.t002){ref-type="table"}).

10.1371/journal.pone.0171076.t002

###### Comparison between different age groups.

![](pone.0171076.t002){#pone.0171076.t002g}

  Characteristics                            ≥60 years (N = 79)       \<60 years (N = 105)     P-value
  ------------------------------------------ ------------------------ ------------------------ -----------
  Age, years                                 69.00(64.25, 77.00)      39.50(28.00, 53.00)      0.000
  Male sex (N, %)                            48(60.76%)               69(65.71%)               0.537
  Oliguria (N, %)                            5(6.33%)                 4(3.81%)                 0.501
  Baseline serum creatinine (μmol/L)         129.60(82.53, 252.90)    95.50(74.30, 161.00)     0.082
  Baseline estimated GFR(mL/min/1.73 m^2^)   44.32(19.75, 83.76)      77.70(39.72, 104.63)     0.011
  Baseline 24 h UTP                          2.47(0.53, 9.09)         3.82(1.89, 9.11)         0.261
  sAlb(g/L)                                  33.00(25.30, 37.40)      33.35(22.00, 40.55)      0.749
  Hb(g/L)                                    102.50(84.25, 127.75)    125.00(105.50, 143.00)   0.000
  ALT(IU/L)                                  11.00(8.00, 20.00)       15.00(10.00, 28.25)      0.029
  AST(U/L)                                   17.00(14.00, 22.50)      17.50(14.00, 26.25)      0.411
  Ca(mmol/L)                                 2.03(1.87, 2.20)         2.11(1.88, 2.22)         0.467
  P(mmol/L)                                  1.34(1.08, 1.69)         1.32(1.10, 1.54)         0.668
  K(mmol/L)                                  3.90(3.40, 4.40)         3.80(3.40, 4.20)         0.735
  HCO~3~^-^(mmol/L)                          24.10(20.40, 26.90)      24.40(21.45, 26.40)      0.471
  hsCRP(mg/L)                                7.38(1.98, 28.70)        1.68(0.53, 4.32)         0.000
  *Cause of AKI*                                                                               *0*.*886*
  Ischemia                                   18(22.78%)               22(20.95%)               
  Nephrotoxin exposure                       16(20.25%)               21(20.00%)               
  Infection                                  19(24.05%)               23(21.90%)               
  Glomerular disease                         12(15.19%)               23(21.90%)               
  Obstruction                                9(11.39%)                12(11.43%)               
  Other                                      5(6.33%)                 4(3.81%)                 
  *AKI stage*                                                                                  0.603
  Stage 1                                    50                       73                       
  Stage 2                                    14                       12                       
  Stage 3                                    15                       20                       
  Peak serum creatinine (μmol/L)             285.35(148.50, 386.03)   191.00(117.35, 301.70)   0.006
  uKIM-1(ng/mg)                              2.75(1.68, 7.44)         1.76(0.77, 6.07)         0.055
  FeNa≥1%                                    68(86.08%)               58(55.24%)               0.000
  RFI≥1%                                     69(87.34%)               67(63.81%)               0.000
  non transient AKI                          55(69.62%)               43(40.95%)               0.000
  Recovery within three months               36(45.57%)               74(70.48%)               0.001
  Ultimate outcome                           48(60.76%)               25(23.81%)               0.000

2.3 Analysis of factors related to poor kidney prognosis in elderly AKI patients {#sec015}
--------------------------------------------------------------------------------

Among the 79 AKI patients ≥60 years old, the transient AKI group included 24 patients and the non transient AKI group included 55 patients. After one year of regular follow-up, the renal function stable group included 31 patients, and the progressive deterioration of renal function included 48 patients ([Fig 1](#pone.0171076.g001){ref-type="fig"}).

### 2.3.1 Comparison between the transient AKI and non transient AKI groups {#sec016}

No differences in age or sex were observed between two groups. After AKI was diagnosed, the peak value of creatinine in the transient AKI group was lower than that in the non transient AKI group, but no significant difference was observed. The uKIM-1 level during the occurrence of AKI in the transient AKI group was significantly lower than that in the non transient AKI group ([Table 3](#pone.0171076.t003){ref-type="table"}, [Fig 2](#pone.0171076.g002){ref-type="fig"}).

![The uKIM-1 level in the transient AKI group was significantly higher than that of the non transient AKI group among elderly AKI patients during the occurrence of AKI.](pone.0171076.g002){#pone.0171076.g002}

10.1371/journal.pone.0171076.t003

###### Comparison between the transient AKI group and the non transient AKI group among elderly patients with AKI.

![](pone.0171076.t003){#pone.0171076.t003g}

  Characteristics                  Transient AKI (N = 24)   non transient AKI (N = 55)   P
  -------------------------------- ------------------------ ---------------------------- -------
  Age, years                       69.00(63.50, 77.00)      69.00(65.00, 78.00)          0.748
  Male sex (N, %)                  15(62.5%)                33(60.00%)                   1.000
  Peak serum creatinine (μmol/L)   183.00(118.98, 340.50)   288.90(195.60, 395.60)       0.148
  uKIM-1(ng/mg)                    1.56(0.72, 2.80)         3.14(2.32, 12.17)            0.000

According to logistic regression analysis, the uKIM-1 level was a risk factor for non transient AKI ([Table 4](#pone.0171076.t004){ref-type="table"}).

10.1371/journal.pone.0171076.t004

###### Logistic regression shows that the uKIM-1 level is a risk factor for non transient AKI.

![](pone.0171076.t004){#pone.0171076.t004g}

                  OR(CI 95%)            P
  --------------- --------------------- -------
  Age                                   0.406
  Sex                                   0.645
  uKIM-1(ng/mg)   1.579(1.037, 2.404)   0.033

Further ROC curve analysis indicated that the area under the curve for non transient AKI according to the uKIM-1 level was 0.812. When the cutoff point was 2.13 ng/mg, the sensitivity and specificity were 80.0% and 76.5%, respectively ([Fig 3](#pone.0171076.g003){ref-type="fig"}).

![ROC-AUC of non transient AKI according to uKIM-1 level.](pone.0171076.g003){#pone.0171076.g003}

### 2.3.2 Comparison between the renal function stable and progressive deterioration of renal function groups {#sec017}

After one year of regular follow-up in elderly AKI patients, no significant differences were observed in the age, sex, and baseline 24 h urine protein quantity between the renal function stable group and progressive deterioration of renal function group.

The baseline creatinine level in the progressive deterioration of renal function group was significantly higher than that of the stable renal function group, whereas the baseline eGFR level in the progressive deterioration of renal function group was significantly lower than that of the stable renal function group. During AKI, significantly higher uKIM-1 levels and peak serum creatinine values were observed in the progression group compared with the stable group ([Table 5](#pone.0171076.t005){ref-type="table"}, [Fig 4](#pone.0171076.g004){ref-type="fig"}).

![The uKIM-1 level of the progressive deterioration of renal function group was significantly higher than that of the renal function stable group among elderly patients with AKI.](pone.0171076.g004){#pone.0171076.g004}

10.1371/journal.pone.0171076.t005

###### Comparison between the progressive deterioration of renal function group and the renal function stable group after the one year of follow-up for elderly patients with AKI.

![](pone.0171076.t005){#pone.0171076.t005g}

  Characteristics                            Renal Function Stable (N = 31)   Progressive deterioration of renal function (N = 48)   P
  ------------------------------------------ -------------------------------- ------------------------------------------------------ -------
  Age, years                                 68.00(64.50, 73.50)              71.00(64.50, 77.50)                                    0.286
  Male sex (N, %)                            20(64.52%)                       28(58.33%)                                             0.642
  Baseline serum creatinine (μmolLl)         93.80(64.00, 203.70)             187.00(87.85, 277.70)                                  0.038
  Baseline estimated GFR(mL/min/1.73 m^2^)   74.43(26.57, 91.21)              31.95(17.58, 62.57)                                    0.022
  Baseline 24 h UTP(g/24 h)                  2.75(0.79, 16.31)                2.19(0.48, 8.34)                                       0.703
  Peak serum creatinine (μmol/L)             174.00(118.95, 302.45)           331.35(214.85, 398.30)                                 0.011
  uKIM-1(ng/mg)                              2.02(1.43, 3.30)                 3.25(1.89, 11.70)                                      0.029

Multifactor Cox regression analysis showed that the uKIM-1 level was an independent risk factor for progressive deterioration of renal function ([Table 6](#pone.0171076.t006){ref-type="table"}).

10.1371/journal.pone.0171076.t006

###### Cox regression shows that uKIM-1 is an independent risk factor for progressive deterioration of renal function.

![](pone.0171076.t006){#pone.0171076.t006g}

                                   RR (CI 95%)           P
  -------------------------------- --------------------- -------
  Age                                                    0.339
  Sex                                                    0.130
  Peak serum creatinine (μmol/L)                         0.173
  uKIM-1(ng/mg)                    1.026(1.003, 1.050)   0.026

Additional ROC curve analysis indicated that the area under the curve for progressive deterioration of renal function as determined by the uKIM-1 level was 0.681. When the cutoff point was 2.46 ng/mg, the sensitivity and specificity were 71.9% and 70.0%, respectively ([Fig 5](#pone.0171076.g005){ref-type="fig"}).

![ROC-AUC of progressive deterioration of renal function predicted by uKIM-1 level.](pone.0171076.g005){#pone.0171076.g005}

A uKIM-1 level \> 2.46 ng/mg in elderly AKI patients was positively correlated with poor kidney prognosis ([Fig 6](#pone.0171076.g006){ref-type="fig"}).

![The uKIM-1 level and kidney prognosis. A uKIM-1 level \> 2.46 ng/mg is positively related to poor prognosis.](pone.0171076.g006){#pone.0171076.g006}

Discussion {#sec018}
==========

AKI is a common clinical syndrome that primarily presents with a rapid decrease in renal function and an accumulation of metabolic waste. For many years, AKI was considered to be a self-limiting disease. However, in recent years, the incidence of CKD has gradually increased in conjunction with an increased incidence of AKI. More studies have reported that some AKI patients do not completely recover and gradually progress to CKD and ESRD, with some patients even requiring permanent kidney replacement therapy \[[@pone.0171076.ref010], [@pone.0171076.ref011]\]. Research data indicated that CKD progression may be influenced by AKI \[[@pone.0171076.ref012], [@pone.0171076.ref013]\]. A total of 184 AKI inpatients were enrolled into the current study, and after one year of regular follow-up, progressive deterioration of renal function was observed in 40% patients. The results demonstrated that AKI may lead to CKD, which is consistent with the results of previous studies \[[@pone.0171076.ref014]\]. It is still unknown why AKI increases the risks of CKD and ESRD. Animal experiments have demonstrated \[[@pone.0171076.ref015]\] that AKI can lead to kidney fibrosis while concurrently damaging the lungs, heart, and liver. Although AKI is generally reversible, in the event of serum creatinine concentration recovery there may be subclinical damage to the kidney and extra-renal organs. This damage will continue, perhaps leading to CKD and even ESRD.

This study observed poor baseline renal function in elderly AKI patients (≥60 years old), and a higher proportion of renal AKI was observed in patients with poorer prognoses. One study that investigated the prognosis of acute interstitial nephritis in elderly patients reported \[[@pone.0171076.ref016]\] that histologically, elderly patients have a higher proportion of glomerulosclerosis, renal interstitial fibrosis and renal tubule atrophy. Elderly patients easily developed AKI cases that more easily progressed to CKD.

Previous studies suggested \[[@pone.0171076.ref017]\] that the uKIM-1 level is a good biomarker for AKI diagnosis. Nejat et al indicated that \[[@pone.0171076.ref018]\] KIM-1 is elevated in pre-renal AKI (AKI caused by compromised renal perfusion) and significantly elevated in renal AKI. However, no systematic verification of biomarkers was performed for elderly AKI patients \[[@pone.0171076.ref002]\]. This study performed a further analysis of elderly AKI patients, and the results indicated that the uKIM-1 level of the non transient AKI group was significantly higher than that of the transient AKI group during the occurrence of AKI. The uKIM-1 level is a risk factor for non transient AKI, and the sensitivity and specificity of uKIM-1 to identify non transient AKI are 80.0% and 76.5%, respectively.

van Timmeren et al examined renal biopsy samples from various renal diseases (n = 102) patients that proximal tubular cells from all patients secreted KIM-1 and that tissue KIM-1 expression was correlated with inflammation. uKIM-1 could reflect the KIM-1 level in tissues and correlate with renal interstitial inflammation and renal function. So Van Timmeren et al \[[@pone.0171076.ref019]\] suggested that KIM-1 is not only a biomarker of acute renal proximal tubule injury but also a marker of renal tubulointerstitial chronic inflammation and fibrosis. Previous studies confirmed \[[@pone.0171076.ref020]\] that uKIM-1 can effectively predict kidney prognosis. In this study, one year of regular follow-up was performed for elderly AKI patients, and the results revealed that the uKIM-1 levels of patients with progressive deterioration of renal function were significantly higher than the levels in the renal function stable group of patients. Multifactor Cox regression analysis demonstrated that the uKIM-1 level is an independent risk factor for progressive deterioration of renal function, and when the uKIM-1 level increased by 1, the risk of progressive deterioration of renal function after one year increased by 2.6%. The sensitivity and specificity of the uKIM-1 level to predict progressive deterioration of renal function were 71.9% and 70.0%, respectively. A uKIM-1 level \>2.46 ng/mg in elderly AKI patients was positively related with poor kidney prognosis.

This single-center study used a small sample size. To further validate the study results, multicenter studies with larger sample sizes are required. In addition, the analysis in this study could not correct for the severity of pre-existing CKD. More advanced CKD is a strong risk factor for AKI. Hsu et al reported that \[[@pone.0171076.ref021]\] progressive deterioration of renal function may be related to advanced CKD but less associated with AKI.

Conclusions {#sec019}
===========

Elderly AKI patients are at risk of progressive deterioration of renal function. uKIM-1 is a good biomarker of AKI in elderly patients, and uKIM-1 levels can effectively distinguish between transient AKI and non transient AKI. In addition, uKIM-1 levels accurately predict the kidney prognosis in elderly AKI patients and may be used as an early screening indicator of poor kidney prognosis. The results of this study can help to develop new treatment strategies to assist clinical physicians in providing earlier interventions to mitigate renal progression after AKI. The renal functions of elderly patients with a history of AKI should be closely monitored.
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